nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-F635F4EF·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Physiology·Basis: Full text·Type: Non-randomized or early-phase trial

Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease.

Di Caro et al.Di Caro, Cho, Thiel et al.·2026·Alzheimer's research & therapy·10.1186/s13195-026-02025-4 ↗

Primary claim

Collectively, plasma biomarker findings in the low p-tau217 subgroup were more robust than in the mITT population. Levels of GFAP were significantly decreased and NfL, Aβ42 and Aβ40 levels trended towards a decrease with zervimesine compared to placebo.

Tentative · multiple nominal subgroup comparisons without multiplicity control or a treatment-by-subgroup interaction test
In brief

Randomized trial biomarker analyses generate plausible enrichment and pharmacodynamic hypotheses, but uncontrolled multiplicity makes the central signals unreliable without replication.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Fragile — the claim's weakest requirement is that the effect depends on the condition stated. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

BACKGROUND: Zervimesine (CT1812) is an investigational brain-penetrant small molecule modulator of the sigma-2 receptor (S2R/TMEM97), currently in clinical development for the treatment of Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) that selectively prevents and displaces the binding of amyloid beta (Aβ) and α-synuclein oligomers from neuronal synapses. Given the mechanism of action, it was hypothesized that zervimesine might be more effective in patients with lower levels of AD pathology. Indeed, in the SHINE trial, a completed Phase 2, randomized, double-blind, clinical trial conducted in participants with AD, a robust, 95%, slowing of cognitive decline, as assessed via ADAS-Cog11, was observed in a pre-specified subgroup of participants with lesser AD pathology (i.e., low p-tau217 subgroup) compared to a 38% slowing in the overall modified intent-to-treat (mITT)) population. METHODS: In SHINE, exploratory plasma biomarkers were assessed using both a targeted and an unbiased, proteomics discovery approach in plasma from participants at baseline and end of study. Treatment effects of zervimesine relative to placebo were assessed in both the mITT population and in a low p-tau217 subgroup, who entered the study with lower (< 1pg/ml) plasma p-tau217 concentrations. Plasma biomarkers Aβ40, Aβ42, GFAP, NfL and BD-tau were assessed using clinically validated targeted assays, along with untargeted TMT-mass spectrometry (MS)-based discovery proteomics followed by bioinformatic, pathway and correlation analyses. RESULTS: Collectively, plasma biomarker findings in the low p-tau217 subgroup were more robust than in the mITT population. Levels of GFAP were significantly decreased and NfL, Aβ42 and Aβ40 levels trended towards a decrease with zervimesine compared to placebo. Proteomics analyses identified candidate pharmacodynamic biomarkers of zervimesine, and gene ontology and pathway analyses pointed to an impact on amyloid biology, trafficking, lipid metabolism, and immune response. Bioinformatics and correlation analyses with GFAP identified biomarkers that may reflect pathway engagement of S2R and/or decreased neuroinflammation. CONCLUSIONS: Exploratory plasma biomarker findings align with the degree of clinical benefit in SHINE mITT and low p-tau217 populations, and support future trial enrichment with patients with lower levels of pathology as defined by lower baseline plasma levels of p-tau217. TRIAL REGISTRATION: July 20th, 2018 ClinicalTrials.gov Identifier NCT03507790 https://clinicaltrials.gov/study/NCT03507790 .

Key Claims

Primary finding · Tentative

Collectively, plasma biomarker findings in the low p-tau217 subgroup were more robust than in the mITT population. Levels of GFAP were significantly decreased and NfL, Aβ42 and Aβ40 levels trended towards a decrease with zervimesine compared to placebo.

Fragile — the claim's weakest requirement is that the effect depends on the condition stated. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

multiple nominal subgroup comparisons without multiplicity control or a treatment-by-subgroup interaction test

Abstract; Results, Figure 1B
Quote verified
Secondary · Tentative

Proteomics analyses identified candidate pharmacodynamic biomarkers of zervimesine, and gene ontology and pathway analyses pointed to an impact on amyloid biology, trafficking, lipid metabolism, and immune response.

small selected proteomic subsets and thousands of unadjusted protein-level tests make individual candidates highly uncertain

Abstract; Results, Figures 2–4
Quote verified
Secondary · Tentative

Exploratory plasma biomarker findings align with the degree of clinical benefit in SHINE mITT and low p-tau217 populations, and support future trial enrichment with patients with lower levels of pathology as defined by lower baseline plasma levels of p-tau217.

a single sample-specific subgroup without formal interaction testing cannot validate a responder-enrichment strategy

Abstract; Conclusion
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Randomized placebo-controlled biomarker source trial

SHINE used a randomized, double-blind, placebo-controlled design, allowing biomarker changes to be compared against a concurrent control rather than an untreated historical series.

↳ Methods, Clinical Trial Design

#contribution

New plasma biomarker dataset

The study extends prior CSF work with targeted plasma markers and untargeted TMT-MS proteomics, creating a useful hypothesis set for later studies.

↳ Background, final paragraphs; Results, Figures 1–6

#positioning

Limitations are explicitly acknowledged

The Limitations section identifies small subgroup samples, unadjusted p-values, false-positive risk, peripheral biomarker ambiguity, and the need for replication.

↳ Limitations

Limitations

#methodological rigour

Multiplicity threatens central biomarker signals

More than 2,000 proteins were tested using unadjusted p-values, while the resulting hit counts are near chance expectations and the Discussion misstates what a 5% test-wise error rate implies for identified proteins.

↳ Methods, Differential Abundance Analyses; Results, Figures 2–4; Discussion, GFAP-correlate paragraph

#methodological rigour

Responder inference lacks interaction testing

The claim that low-p-tau217 findings are more robust relies on nominal subgroup results rather than a reported treatment-by-subgroup interaction, limiting the enrichment inference.

↳ Abstract; Results, Figure 1B; Conclusion

#reporting

Conclusions exceed exploratory evidence

Phrases such as “leads to positive changes” and “identify a patient population more likely to respond” give small, multiplicity-exposed subgroup findings greater certainty than the analysis supports.

↳ Conclusion

Does this match your read? Add your assessment ↓

Nabu Commentary

The randomized placebo-controlled parent trial and validated targeted assays make the plasma biomarker dataset a useful exploratory contribution. The main methodological limitation is extensive nominal testing: targeted outcomes span multiple biomarkers and populations, while more than 2,000 proteins and numerous correlations were screened without protein-level multiplicity control. The selected proteomic sample and n=16 GFAP-correlation analysis further restrict certainty, and Figure 1 uses inconsistent population labels. Although the Limitations section acknowledges false-positive risk and replication needs, the Abstract and Conclusion still frame the findings as biological impact and identification of likely responders.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.0±0.2

Contribution
3.0

The study adds targeted plasma biomarker and discovery-proteomic observations from a randomized phase-2 trial, extending previously reported CSF work. The advance remains incremental because the principal findings are exploratory and require replication.

Abstract; Background, final paragraphs; Results, Figures 1–6

“Proteomics analyses identified candidate pharmacodynamic biomarkers of zervimesine”

Methodological Rigour
2.8

The randomized placebo-controlled source trial and validated targeted assays support comparative biomarker analysis. Methodological Rigour is limited by selected small proteomic subsets, extensive unadjusted testing, fragile n=16 correlations, and the absence of a subgroup interaction test.

Methods, Clinical Trial Design; Untargeted Discovery TMT-MS Proteomics Assessments; Differential Abundance Analyses; Results, Figures 1–4

“significance assessed using an unadjusted p-value criterion p ≤ 0.05”

Reporting
3.0

The manuscript follows a coherent sequence from targeted biomarkers to proteomics, correlations, and pathway interpretation. Its clarity is reduced by inconsistent Figure 1 denominators and conclusion-level language that presents exploratory subgroup evidence as identifying likely responders.

Figure 1 legend; Abstract; Conclusion

“enabled us to identify a patient population more likely to respond”

Positioning
3.2

The paper discusses relevant p-tau217, anti-amyloid, prior SHINE, and CSF-proteomic literature and explicitly acknowledges small samples and unadjusted testing. The resulting uncertainty is not fully reflected in claims of biological impact and enrichment utility.

Background; Discussion; Limitations; Conclusion

“candidate biomarkers identified should be viewed with caution”

Lower confidence on Methodological Rigour — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyNoted

The 15 proteins overlapping the GFAP correlates and differential-abundance results are described using different significance thresholds; their individual p-values are not supplied, so the number meeting the stricter threshold cannot be determined.

Conflict of interest: not stated · Ethics approval: not stated · Preregistration: declared · Data availability: not stated · Code availability: not stated

Reference IntegrityNoted

53 references in manuscript 45 of 45 checkable references found in an index 2 are books, websites or datasets — counted, but not index-checkable 6 could not be checked — not the same as no match found

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSpecified
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The biomarker effects come from a single Phase 2 trial's exploratory pre-specified subgroup, and the authors state replication in larger trials is warranted.

From the paper
“support future trial enrichment with patients with lower levels of pathology as defined by lower baseline plasma levels of p-tau217”

The paper names the actors (Phase 3 trial sponsors/teams), the decision (patient enrichment for trials), and the method (a baseline plasma p-tau217 cutoff below 1 pg/ml).

Pathway

Drug developers and Phase 3 trial teams would use the baseline plasma p-tau217 cutoff to enroll AD patients more likely to respond to zervimesine.

Barrier

Exploratory, small subgroup analyses with unadjusted statistics require replication in larger independent trials before the biomarkers can guide enrollment.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's disease

    2026 · Neurology and psychiatry

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. Divergent toxicity mechanisms of amyloid-beta aggregates arising from a single aggregation reaction

    2026 · Basic medicine

    Primary claim

    aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity

    Tentative
    Evidence Score
    2.8±0.2
    Reliability
    Caveats
  3. A timeline of tau-mediated synaptotoxicity

    2026 · Basic medicine

    Primary claim

    even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    No concerns

How the rubric works →